While Others Worry, You Can Profit

0 | By Michael A. Robinson

As the song goes, “You can’t always get what you want.”

This applies well to last week’s announcement of plans for full legalization of adult marijuana use in Canada. During that April 13 event, the Trudeau government said all will be in place by July 1, 2018.

But there was a “problem” – at least according to some legalization advocates and analysts.

Instead of laying everything out precisely, legalization in Canada is still evolving. For instance, individual Canadian provinces will have a lot of say about where and when marijuana can be sold, how old buyers can be, and taxation.

So there is much more work to do than was hinted by the government when it leaked preliminary legalization details back on March 27.

And out come the handwringers – fretting that legalization will be delayed or… maybe… never even happen.

Don’t join these worrywarts.

Nothing here shatters the lucrative reality that double-, triple, or even quadruple-digit gains are on the way for the five stocks I included my latest report – How to Make a Fast Fortune on Canada’s Upcoming Total Legalization of Marijuana.

In fact, there are four reasons why you don’t need to lose sleep.

Here they are…

Sometimes the Road to Wealth Is Paved by Tech – and Toothpaste

0 | By Michael A. Robinson

Even if your name is Bill Gates or Warren Buffet, $3 billion is a lot of money.

And even if you’re finding that the years fly by as you get older, 12 years is a long time.

Yet, on average, that’s what it takes for a biopharmaceutical company to develop a new drug from discovery stage to pharmacy shelves.

Moreover, the ratio of researched treatments to eventually approved therapies – at somewhere between 5,000-to-1 and 10,000-to-1 – may be even more depressing for drug developers.

However, if all goes as planned – if a drug makes it into your medicine cabinet – then they’ll make that money back… and more. Particularly if they come up with a real blockbuster.

But still, so much vital R&D money goes down the drain.

Little wonder then that a major drug player might want to realign its operations to be less focused on the boom-and bust cycle of drug research.

Today, we’ll explore a Big Pharma leader that’s doing just that.

It got started on this move three years ago.

It just made a big promotion that will serve as a further catalyst in this same direction.

And its stock could make you 20% a year – or more – for a long time to come.

Read on…

Recent Articles